Real-world outcomes of serplulimab-based therapy in unresectable locally advanced or metastatic pancreatic cancer

作者
Liang Gui,Changjiang Sun,Li Chen,Ting Yin,Fei Yan,Ya Huang,Zijian Sun,Yan Sun
出处
期刊:BMC Cancer [BioMed Central]
标识
DOI:10.1186/s12885-026-16783-9
摘要

Immunotherapy benefits many solid tumors, yet efficacy in pancreatic cancer (PC) remains limited given its immunologically cold phenotype. We evaluated the real-world effectiveness, safety, and treatment patterns of serplulimab-based regimens in unresectable locally advanced or metastatic PC. This two-center observational study retrospectively included adults with pathologically confirmed advanced PC who received serplulimab-based therapy as first- or later-line treatment. Short-term efficacy was assessed per RECIST v1.1, safety per CTCAE v5.0, and long-term benefit by overall survival (OS). Among the 42 included patients, 24 received first-line (1 L) therapy and 18 received second-line or later (≥ 2 L) therapy. At a median follow-up of 17.7 months, the objective response rate (ORR) in the 1 L group was 25.0% (95% CI: 9.8–46.7%) and the disease control rate (DCR) was 83.3% (95% CI: 62.6–95.3%); in the ≥2 L group, the ORR was 22.2% (95% CI: 6.4–47.6%) and the DCR was 83.3% (95% CI: 58.6–96.4%). Median progression‑free survival was 6.2 months (95% CI: 4.4–9.3) in the 1 L group and 5.7 months (95% CI: 3.2–NR) in the ≥2 L group. Median OS was 10.3 months (95% CI: 8.0–12.9) in the 1 L group and 9.1 months (95% CI: 5.4–NR) in the ≥2 L group. Adverse events (AEs) occurred in 78.6%, predominantly hematologic; grade 3 or higher immune-related AEs occurred in 4.8%. Serplulimab-based combinations showed preliminary antitumor activity with a manageable safety profile in advanced PC across both first-line and later-line settings. These real-world data generate hypotheses for larger, biomarker-integrated prospective studies to optimize combinations and improve the durability of benefit.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xx发布了新的文献求助10
刚刚
刚刚
吴遥完成签到,获得积分10
刚刚
dong8898完成签到,获得积分10
刚刚
聚乙二醇发布了新的文献求助10
刚刚
WY完成签到 ,获得积分10
1秒前
wanggeng完成签到,获得积分10
1秒前
义气千风完成签到,获得积分10
1秒前
molihuakai的应助被淡然雅寒采纳,获得10
1秒前
缥缈伊发布了新的文献求助10
1秒前
自信的涵菡完成签到,获得积分10
1秒前
科研路上的干饭桶完成签到,获得积分10
2秒前
今后的应助被ljs采纳,获得10
2秒前
2秒前
Hello的应助被高高小兔子采纳,获得10
3秒前
热心的甜瓜完成签到,获得积分10
3秒前
4秒前
4秒前
coconut完成签到,获得积分10
4秒前
4秒前
bkagyin的应助被tang采纳,获得10
5秒前
5秒前
我不吃芒果完成签到,获得积分10
5秒前
阿文完成签到,获得积分10
5秒前
华仔的应助被anbude采纳,获得10
5秒前
5秒前
5秒前
马111发布了新的文献求助10
6秒前
蝈蝈完成签到,获得积分10
6秒前
hbhsjk发布了新的文献求助10
6秒前
水煮电吹风的应助被刘之捷采纳,获得10
6秒前
6秒前
7秒前
小二郎的应助被youyyuy采纳,获得10
7秒前
zhouzhou完成签到,获得积分10
7秒前
上课呢完成签到 ,获得积分10
7秒前
psycancan完成签到 ,获得积分10
7秒前
8秒前
现代的向珊完成签到,获得积分20
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287